Erdafitinib 3 mg, 4 mg, 5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 3 mg, 4 mg, 5 mg

Reference Brands: Balversa (USA)

Category: Oncology Cancer Care

Erdafitinib is a Oncology Cancer Care product available as Tablets in strengths 3 mg, 4 mg, 5 mg. It corresponds to the reference brand Balversa (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Erdafitinib, marketed under the brand name Balversa, is an oral anti-cancer medication and a small-molecule inhibitor of fibroblast growth factor receptors (FGFRs). FGFRs are a subset of tyrosine kinases that, when unregulated, contribute to tumor cell proliferation, differentiation, angiogenesis, and survival. By selectively inhibiting FGFR activity, erdafitinib interferes with these processes, helping to slow or stop the growth of cancer cells that rely on FGFR signaling.

Erdafitinib is specifically indicated in the United States for the treatment of adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations, particularly in patients whose disease has progressed following at least one prior systemic therapy. Developed initially by Astex Pharmaceuticals and licensed to Janssen Pharmaceuticals for further clinical development, erdafitinib represents a precision oncology therapy targeting tumors with defined genetic profiles. Its oral administration and targeted mechanism of action provide a convenient and effective treatment option for patients with FGFR-driven malignancies, offering a personalized approach to cancer management.